https://www.selleckchem.com/pr....oducts/mcc950-sodium
Objectives Although the PARAGON-HF trial failed to reach its primary endpoint, subgroups of patients with heart failure with preserved ejection fraction (HFpEF) still appear to benefit from Sacubitril/Valsartan therapy. As HFpEF patients with pulmonary hypertension display a specifically high mortality and morbidity, we evaluated the effect of Sacubitril/Valsartan in this subgroup of HFpEF patients. Methods In this retrospective case-series of 18 patients with HFpEF and pulmonary hypertension, right heart catheterisation (RHC
Aimer
Commentaire
Partagez
